Pharmafile Logo
Pharmafocus logo
Advanced Search
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016
Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …

News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

News
astrazeneca_building_white

AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016
Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …

News
allergan_waco

Allergan breaks ground on $200 million expansion at Texas site

April 26, 2016
Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco

Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …

News
novartis_mit_us

Novartis exploring almost $14-billion stake sale in Roche – reports

April 26, 2016
Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale

Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …

News
gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …

News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …

Appointment
test_results

FDA, WHO criticise integrity of data at contract research firm Semler

April 25, 2016
Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research

The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …

News
stocks1

Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…

April 25, 2016
Research and Development, Sales and Marketing

With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …

Feature

Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study

April 25, 2016
Research and Development, Sales and Marketing

Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …

News
stocks2

Valeant receives further default notices due to its delayed 10-K filing

April 25, 2016
Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry

Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …

News
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

News
astrazeneca_sign_sky

AstraZeneca to sequence genomes to develop new drugs

April 22, 2016
Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute

AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …

News
trials

AbbVie announces further industry and academic collaborations

April 22, 2016
Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …

News
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …

News
actelion_logo

Actelion ups outlook for 2016, reports Q1 net income up 12%

April 22, 2016
Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook

Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …

News
jevtana

A win for Sanofi on Jevtana after NICE reverses guidance

April 22, 2016
Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …

News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016
Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …

News

PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference

April 21, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation

Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …

News
Press release
The Gateway to Local Adoption Series

Latest content

NICE backs atogepant for acute migraine treatment

June 12, 2026

Survey data highlight challenges in anaphylaxis treatment adherence

June 11, 2026

Hansa Biopharma appoints Fredrik Röök as VP Business Development

June 11, 2026

Sofinnova and AWS collaborate on AI tools for life sciences

June 10, 2026

First European approval given to non-opioid treatment for chronic low back pain

June 9, 2026